UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 5, 2010
 
MAP PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
 
         
Delaware
  
001-33719
  
20-0507047
(State or Other Jurisdiction
of Incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
     
2400 Bayshore Parkway, Suite 200,
Mountain View, CA
  
94043
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (650) 386-3100
 
 
(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 
 
Item 2.02
Results of Operations and Financial Condition
 
On November 5, 2010, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its third quarter ended September 30, 2010. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information in this Item 2.02 of this Current Report on Form 8-K and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 of this Current Report on Form 8-K and the press release referenced herein is not incorporated by reference into any filings of MAP under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing, unless explicitly incorporated by specific reference into such filing.
 
 
Item 9.01
Financial Statements and Exhibits
 
 
(d)
Exhibits
 
     
Exhibit No.
  
Description
   
99.1
  
Press Release of MAP Pharmaceuticals, Inc., dated November 5, 2010


 

 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 5, 2010
 
 
MAP PHARMACEUTICALS, INC.
       
 
By:
  
/s/ Charlene A. Friedman
  
 
Name:
  
Charlene A. Friedman
  
 
Title:
  
Vice President, General Counsel and Secretary


 

 
 
 
 
INDEX TO EXHIBITS FILED WITH
THE CURRENT REPORT ON FORM 8-K DATED NOVEMBER 5, 2010
 
     
Exhibit
  
Description
   
99.1
  
Press Release of MAP Pharmaceuticals, Inc., dated November 5, 2010.